OUP user menu

Antithrombin therapy, antiplatelet therapy and percutaneous coronary intervention: rationale and design of the SYNERGY trial

J.J. Ferguson
DOI: http://dx.doi.org/10.1093/eurheartj/4.suppl_E.E2 E2-E9 First published online: 1 May 2002

Abstract

Although low-molecular-weight heparins (LMWHs) have been shown to be equivalent or superior to unfractionated heparin for the management of patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI), a number of clinical issues remain. Among them are the safety of bringing patients to the catheterization laboratory and the use of glycoprotein (GP)Ilb/Illa antagonists. The Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors (SYNERGY) trial is a randomized study comparing the safety and efficacy of unfractionated heparin and the LMWH enoxaparin in high-risk, invasively managed UA/NSTEMI patients who are likely to receive GPIIb/IIIa antagonists.

  • Heparin
  • low-molecular-weight heparin
  • percutaneous atherectomy
  • platelet glycoprotein IIb/IIIa receptor antagonist/inhibitor
  • unstable angina